Table 2. Analysis of the variables variation during interdisciplinary therapy on anthropometric and metabolic profile according FGF21 response.
| All sample (n = 31) | Increased FGF21 (n = 16) | Decreased FGF21 (n = 15) | |
|---|---|---|---|
| Body weight (kg) | -3.19 ± 2.99 | -2.68 ± 2.61 | -3.74 ± 3.35 |
| Body mass index (kg/m2) | -1.20 ± 1.14 | -0.99 ± 0.97 | -1.43 ± 1.30 |
| Neck circumference (cm) | -0.75 ± 0.81 | -0.79 ± 0.67 | -0.72 ± 0.98 |
| Waist circumference (cm) | -3.51 ± 3.48 | -3.07 ± 3.04 | -4.02 ± 4.00 |
| Abdominal circumference (cm) | -3.15 ± 3.78 | -3.99 ± 3.16 | -2.17 ± 4.32 |
| Hip circumference (cm) | -2.93 ± 3.90 | -2.03 ± 3.13 | -3.97 ± 4.54 |
| Body fat mass (%) | -1.68 ± 4.21 | -1.63 ± 5.06 | -1.74 ± 3.25 |
| Body lean mass (kg) | -0.89 ± 3.96 | -1.29 ± 5.13 | -0.49 ± 2.43 |
| Glucose (mg/dL) | 0.42 ± 10.09 | 2.50 ± 8.74 | -1.80 ± 11.23 |
| Insulin (uIU/mL) | -0.52 ± 4.77 | 0.20 ± 3.30 | -1.25 ± 5.92 |
| HOMA-IR | -0.144 ± 1.24 | 0.06 ± 0.8 | -0.35 ± 1.54 |
| HOMA-AD | -0.35 ± 0.84 | -0.36 ± 0.81 | -0.35 ± 0.90 |
| Adiponectin (pg/mL) | 1.26 ± 2.11 | 1.90 ± 2.30 | 0.63 ± 1.74 |
| Leptin (ng/mL) | -14.48 ± 13.75 | -20.44 ± 14.65 | -8.53 ± 10.05d |
| Adiponectin/leptin | 0.07 ± 0.09 | 0.10 ± 0.11 | 0.04 ± 0.05d |
| ANP (pg/mL) | -18.40 ± 443.04 | 16.16 ± 436.48 | -52.96 ± 464.57 |
| FGF21 (pg/mL) | 53.58 ± 140.09 | 129.19 ± 161.46 | -27.08 ± 24.86d |
HOMA-IR: homeostasis model assessment-insulin resistance; HOMA-AD: HOMA-adiponectin; ANP: atrial natriuretic peptide; FGF21: human fibroblast growth factor 21.
d
Statistical difference between increased and decreased FGF21 groups. Comparisons between groups were performed by T-test for independent groups.